CanSino Biologics starts phase 1 trial for inhaled TB booster vaccine

CanSino Biologics Inc. (HKEX:6185) has announced the initiation of a phase 1 clinical trial for its inhaled tuberculosis vaccine (Adenovirus Type 5 Vector), known as "inhaled TB Booster," in Indonesia. The company confirmed that the first patient for the phase 1 clinical trial has been formally enrolled. This trial aims to assess the safety and immunogenicity of a single dose of the inhaled TB Booster in adults aged 18 to 49 years.

The inhaled TB Booster represents an advancement from the company’s first-generation tuberculosis booster vaccine, which completed phase 1a and 1b clinical trials in Canada. That earlier version demonstrated safety and effectiveness as a Bacillus Calmette-Guerin booster vaccine, along with superior mucosal immunity. The current inhaled version incorporates additional antigen components and leverages the company's established inhalation pharmacy and quality control system, developed from its COVID-19 vaccine for inhalation.

CanSino Biologics anticipates the inhaled TB Booster, delivered via aerosol inhalation, will stimulate an immune response in the lungs to clear tuberculosis bacilli, control latent infection, and prevent infections. The company’s board of directors includes Dr. Xuefeng YU as chairman. Shareholders and potential investors are advised to exercise caution.